Profile data is unavailable for this security.
About the company
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
- Revenue in USD (TTM)0.00
- Net income in USD-31.05m
- Incorporated1983
- Employees43.00
- LocationCEL-SCI CorpSUITE 802, 8229 BOONE BLVD .VIENNA 22182United StatesUSA
- Phone+1 (703) 506-9460
- Fax+1 (703) 506-9471
- Websitehttps://cel-sci.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beyondspring Inc | 1.75m | -21.03m | 88.99m | 35.00 | -- | -- | -- | 50.82 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Spero Therapeutics Inc | 103.78m | 22.81m | 89.46m | 46.00 | 4.09 | 0.823 | 3.86 | 0.862 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Chimerix Inc | 41.00k | -82.59m | 89.63m | 72.00 | -- | 0.5148 | -- | 2,186.10 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Armata Pharmaceuticals Inc | 4.53m | -69.05m | 90.75m | 66.00 | -- | -- | -- | 20.04 | -1.91 | -1.91 | 0.1255 | -0.8877 | 0.0466 | -- | -- | 68,621.21 | -71.11 | -59.78 | -90.34 | -72.70 | -- | -- | -1,524.51 | -1,113.72 | -- | -1.68 | 1.64 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Angion Biomedica Corp | 0.00 | -35.19m | 91.88m | 32.00 | -- | 7.58 | -- | -- | -8.81 | -8.81 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -88.05 | -105.91 | -110.32 | -331.69 | -- | -- | -- | -712.81 | -- | -700.88 | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 1.00m | -59.69m | 92.48m | 47.00 | -- | 3.47 | -- | 92.48 | -1.39 | -1.39 | 0.0233 | 0.5009 | 0.0134 | -- | 0.3949 | 21,276.60 | -79.73 | -48.44 | -87.55 | -51.56 | -- | -- | -5,968.50 | -1,267.25 | -- | -- | 0.748 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Allovir Inc | 0.00 | -190.42m | 92.67m | 112.00 | -- | 0.6315 | -- | -- | -1.83 | -1.83 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -81.40 | -52.85 | -91.73 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -31.05m | 92.84m | 43.00 | -- | 6.80 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| BioXcel Therapeutics Inc | 1.38m | -179.05m | 92.96m | 74.00 | -- | -- | -- | 67.36 | -6.16 | -6.16 | 0.0474 | -1.89 | 0.0099 | 0.6343 | 8.65 | 18,648.65 | -128.10 | -74.57 | -163.23 | -84.06 | 8.62 | -- | -12,974.86 | -32,300.74 | 2.57 | -21.87 | 2.28 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Aclaris Therapeutics Inc | 31.25m | -88.48m | 93.36m | 91.00 | -- | 0.5909 | -- | 2.99 | -1.27 | -1.27 | 0.4477 | 2.22 | 0.1383 | -- | 79.92 | 343,395.60 | -39.15 | -47.29 | -44.34 | -53.87 | 42.14 | 44.00 | -283.15 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Curis Inc | 10.02m | -47.41m | 95.31m | 48.00 | -- | 4.85 | -- | 9.51 | -9.02 | -9.02 | 1.89 | 3.34 | 0.1077 | -- | 3.47 | 208,812.50 | -50.95 | -37.25 | -58.32 | -41.12 | 97.88 | 96.05 | -473.04 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Clearside Biomedical Inc | 8.23m | -32.49m | 95.66m | 30.00 | -- | -- | -- | 11.63 | -0.5263 | -0.5263 | 0.1331 | -0.2532 | 0.1928 | -- | 96.78 | 274,200.00 | -76.15 | -63.57 | -89.34 | -81.77 | 95.64 | -- | -394.91 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Eton Pharmaceuticals Inc | 31.64m | -936.00k | 96.33m | 30.00 | -- | 6.22 | -- | 3.04 | -0.0389 | -0.0389 | 1.23 | 0.6025 | 1.11 | 14.42 | 12.02 | 1,054,733.00 | -3.30 | -46.22 | -5.49 | -58.20 | 66.56 | 72.16 | -2.96 | -76.86 | 1.60 | -- | 0.258 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Anixa Biosciences Inc | 210.00k | -10.74m | 96.34m | 4.00 | -- | 3.90 | -- | 458.75 | -0.3451 | -0.3451 | 0.0068 | 0.7749 | 0.0078 | -- | 0.7807 | 52,500.00 | -40.49 | -59.69 | -41.26 | -62.61 | -- | -- | -5,174.29 | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
Data as of May 07 2024. Currency figures normalised to CEL-SCI Corp's reporting currency: US Dollar USD
9.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.06m | 3.82% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 747.85k | 1.39% |
| Geode Capital Management LLCas of 31 Dec 2023 | 478.40k | 0.89% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 388.31k | 0.72% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2023 | 358.14k | 0.66% |
| D.A. Davidson & Co. (Investment Management)as of 31 Dec 2023 | 290.93k | 0.54% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 194.01k | 0.36% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2023 | 151.33k | 0.28% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 149.90k | 0.28% |
| Thoroughbred Financial Services LLCas of 31 Dec 2023 | 126.76k | 0.24% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
